- 面议
起订量：
79853 Anti-CD19 CAR / NFAT (Luciferase) Reporter Jurkat Cell Line (CD19 SCFV-CD28-4-1BB-CD3ζ)
- 型号
- 79853
该企业相似产品
BPS Bioscience专注于开发高质量的产品，提供优质的客户服务，并维护稳健的质量管理体系。BPS Bioscience现已通过ISO 9001:2015认证，确保质量的持续监控和持续改进，从而满足客户需求。
BPS Bioscience产品涉及临床前药物开发过程的每个阶段。其中部分产品可以用于许多研究阶段。BPS Bioscience将继续丰富我们的产品线，希望以此推动了整个早期药物研发过程。
详细信息
Anti-CD19 CAR/NFAT (Luciferase) Reporter Jurkat Cell Line (CD19 SCFV-CD28-4-1BB-CD3ζ) is a stable cell line expressing an anti-CD19 CAR and an NFAT-dependent luciferase reporter. The reporter cell line has been validated for anti- CD19 expression by flow cytometry, and for luciferase reporter activation by target cells, including the CD19 CHO cell line. Anti-CD19 CAR consists of the anti-CD19 scFv linked to 3rd generation CAR containing the CD28, 4-1BB co-stimulatory domains and the CD3ζ signaling domain.
The cell line can be used for primary screening and functional validation of anti-CD19 CAR construct and lentivirus before testing is performed in primary T cells.
Figure 1: Lenti-vector used to generate anti-CD19 CAR lentivirus.
Figure 2. Schematic of anti-CD19 CAR.
Anti-CD19 (scFv) is linked to the 3rd generation CAR with CD28 transmembrane and costimulatory domains, 4-1BB, and CD3ζ components.
Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.
